Kurome Therapeutics, Inc., a late pre clinical stage biotech company developing novel IRAK1/4 inhibitors for oncology indications, today announced two abstracts have been accepted for oral and poster presentations at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 9-13, 2022, in New Orleans. The presentations highlight preclinical data supporting the importance of inhibiting both IRAK1 and IRAK4 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).
ASH 2022 Presentation Details:
Oral Presentation Title: IRAK1 Contributes to IRAK4 Inhibitor Resistance Via Non-Canonical Signaling Mechanisms in MDS/AML
Presenter and Lead Author: Josh Bennett, BS, Cincinnati Children’s Hospital Medical Center, and Daniel T. Starczynowski, PhD, Cincinnati Children’s Hospital Medical Center
Session Name: Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Immune Signaling and Antibody-therapeutic Targeting in Myeloid Neoplasms
Presentation Date/Time: Monday, December 12, 2022, at 4:30 p.m. CST
Location: Ernest N. Morial Convention Center, 353-355
Poster Presentation Title: Inhibition of Both IRAK1 and IRAK4 Is Required for Complete Suppression of NF-Kb Signaling across Multiple Receptor-Mediated Pathways in MDS and AML
Publication Number: 2647
Authors: Jan S Rosenbaum, PhD, Kurome Therapeutics, Scott B. Hoyt, Ph.D., National Center for Advancing Translational Sciences, National Institutes of Health, Amal S. Kolt, MS, Kurome Therapeutics, Daniel A Luedtke, PhD, Kurome Therapeutics, Craig J. Thomas, PhD, National Center for Advancing Translational Sciences, National Institutes of Health, and Daniel T. Starczynowski, PhD, Cincinnati Children’s Hospital Medical Center
Session Name: Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II
Session Date/Time: Sunday, December 11, 2022, 6:00 - 8:00 p.m. CST
Location: Ernest N. Morial Convention Center, Hall D
Abstracts are available on the ASH meeting website at www.hematology.org
About Kurome Therapeutics
Kurome® Therapeutics is a late-stage preclinical company focused on targeting innate immune signaling pathways in cancer. Kurome is developing a series of potent IRAK1/4 and panFLT3 inhibitors that work by targeting key cancer survival pathways. The company’s first to market indications will be Acute Myeloid Leukemia (AML) and high-risk MDS. Kurome is also developing a companion diagnostic and biomarker program.
Please find more information at www.kurometherapeutics.com
NOTE: Daniel Starczynowks’s disclosures pertaining to Kurome Therapeutics include: Consultancy, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Research Funding
View source version on businesswire.com: https://www.businesswire.com/news/home/20221206005474/en/
Contacts
Kurome Therapeutics
Mike Pistone
VP, Business Development
pistone@kurometx.com
